Pfizer's Abrysvo vaccine is highly effective in preventing severe lower respiratory tract illness in those at high risk from the Respiratory Syncytial Virus (RSV). Japan, like other countries, is promoting RSV vaccination among pregnant women, but it needs to do better. However, Japan is enduring a state of broad vaccine hesitancy. In light of our experiences with Japan's past failures in promoting the Human Papillomavirus vaccine, we describe some of the challenges encountered in promoting vaccines and discuss possible solutions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126767 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.
Nanomedicine (Lond)
January 2025
Clinical Laboratory Science Section, Institute of Medical Science Technology, Universiti Kuala Lumpur, Kajang, Selangor, Malaysia.
Phytochemicals are typically natural bioactive compounds or metabolites produced by plants. Phytochemical-loaded nanocarrier systems, designed to overcome bioavailability limitations and enhance therapeutic effects, have garnered significant attention in recent years. The coronavirus disease 2019 (COVID-19) pandemic has intensified interest in the therapeutic application of phytochemicals to combat viral infections.
View Article and Find Full Text PDFRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Lancet Infect Dis
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Methods: We used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant stabilised prefusion F protein RSV vaccine versus no vaccination among veterans aged 60 years and older.
RSV vaccines: an elixir for healthy ageing?
Lancet Infect Dis
January 2025
Usher Institute, University of Edinburgh, Edinburgh EH16 4UX, UK.
Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
Vaccine
January 2025
Division of Epidemiology, School of Public Health, Tohoku University Graduate School of Medicine, Japan.
Pfizer's Abrysvo vaccine is highly effective in preventing severe lower respiratory tract illness in those at high risk from the Respiratory Syncytial Virus (RSV). Japan, like other countries, is promoting RSV vaccination among pregnant women, but it needs to do better. However, Japan is enduring a state of broad vaccine hesitancy.
View Article and Find Full Text PDFProtective or limited? Maternal antibodies and RSV-associated lower respiratory tract infection in hospitalized infants aged 28-90 days.
Front Immunol
January 2025
Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
Background: Respiratory syncytial virus (RSV) is a major cause of severe health problems in newborns and young children. The protective role and limitations of serum maternal RSV antibodies in infants under 3 months remain controversial.
Methods: A two-center prospective study from 2020 to 2023 recruited infants (n=286) admitted to the respiratory departments of two children's hospitals in southwestern and southeastern China during RSV epidemic.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!